AbbVie/Janssen’s Imbruvica filed for graft-versus-host-disease

5th April 2017 Uncategorised 0

US regulators have agreed to review AbbVie and Janssen’s Imbruvica for previously treated chronic graft-versus-host-disease (cGVHD), a severe, potentially life-threatening consequence of stem cell or bone marrow transplant.

More: AbbVie/Janssen’s Imbruvica filed for graft-versus-host-disease
Source: News